摘要
目的 探讨重组人白细胞介素-2（rhIL-2）联合顺铂（DDP）腔内注射治疗癌性胸腔积液的临床疗效和不良反应.方法 将166例恶性肿瘤并发胸腔积液患者随机分为两组,其中采用rhIL-2联合DDP腔内注射治疗82例为治疗组,单纯DDP治疗84例为对照组.随访2个月,观察两组患者的临床疗效及不良反应发生情况.结果 治疗组症状完全缓解25例,部分缓解38例,无效10例,总有效率为76.83%;对照组症状均未完全缓解,部分缓解40例,无效44例,总有效率为47.62%;治疗组总有效率明显高于对照组（x2=6.48,P〈0.05）.治疗组血常规异常2例,肝肾功能异常1例,临床反应24例,不良反应发生率为32.93%;对照组血常规异常3例,肝肾功能异常2例,临床反应22例,不良反应发生率为32.93%;治疗组与对照组不良反应发生率比较差异无统计学意义（X2=0.83,P〉0.05）.结论 rhIL-2联合DDP腔内注射治疗癌性胸腔积液安全有效,可以作为临床上治疗癌性胸腔积液选择方法之一.
Objective To evaluate the clinical efficacy and observe the adverse reactions of intrathoracic cavity injection of recombinant human interleukin-2 （rhIL-2） combined with cisplatin （DDP） for treatment of malignant pleural effusion. Methods One hundred and sixty-six patients with cancer complicated by pleural effusion were randomly divided into two groups. The control group （n ： 84） received only DDP treatment, while the treatment group （n~ 82） accepted intra-thoracic cavity injection of rhIL-2 combined with DDP. During 2 months of follow-up, the clinical efficacy and side effects in the two groups were observed. Results In the treatment group, there were 25 cases with complete remission of symptoms, 38 cases with partial remission and 10 cases ineffective, the total effective rate being 76.83%; in the control group, there were 40 cases with partial remission, 44 cases ineffective, but no complete remission of pleural effusion, the total effective rate being 47.62%. The total effective rate in treatment group was significantly higher than that in the control group （x^2=6.48, P〈0.05）. In the treatment group, there were 2 cases with blood routine abnormality, 1 case with liver and kidney dysfunction, 24 cases with clinical response, the incidence of adverse reaction being 32.93 % ; in the control group, there were 3 cases with blood routine abnormality, 2 cases with liver and kidney dysfunction, 22 cases with clinical response, the incidence of adverse reaction being 32.93%. The difference in the incidence of adverse reaction between the two groups had no statistical significance （x^2=0.83, P〉0.05）. Conclusion Intra-thoracic cavity injection of rhIL-2 combined with DDP is safe and effective for treatment of malignant pleural effusion, and it can be selected as one of the clinical therapies for the disease.
出处
《中国中西医结合急救杂志》
CAS
北大核心
2010年第5期314-315,共2页
Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care
关键词
癌性胸腔积液
重组人白细胞介素-2
顺铂
Malignant pleural effusion
Human recombinant interleukin-2
Cisplatin
